Leqselvi (deuruxolitinib) / Sun Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Leqselvi (deuruxolitinib) / Sun Pharma
2020-002704-40: Study to assess the efficacy and safety following administration of CTP-543 in adult patients with moderate to severe alopecia areata

Not yet recruiting
3
700
Europe
deuruxolitinib (Tablet 8 mg every 12 hours), deuruxolitinib (Tablet 12 mg every 12 hours), CTP-543, Tablet
Concert Pharmaceuticals, Inc, Concert Pharmaceuticals, Inc.
Moderate to severe alopecia areata in adult patients, Episode of hair loss associated with alopecia areata in adult patients, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
NCT05041803 / 2021-002365-18: European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults with Alopecia Areata

Completed
3
407
Europe
CTP-543
Concert Pharmaceuticals
Alopecia Areata
07/24
07/24
NCT03898479: Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Active, not recruiting
2/3
1000
Canada, US
CTP-543
Concert Pharmaceuticals
Alopecia Areata
05/25
05/25
NCT04784533: A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Completed
2
317
US
CTP-543, Placebo
Concert Pharmaceuticals
Alopecia Areata
05/23
05/23

Download Options